Vicapsys Completes Reverse Merger, Acquires NitroMist, and Plans Manufacturing Facility
VICP filed a M&A and Partnerships on elevated volume (3.7× avg).
Summary
Vicapsys Life Sciences has completed its reverse merger with Stateline Distributors of Puerto Rico, effective September 3, 2026, making Stateline a wholly owned subsidiary. The combined company gains a DSCSA-compliant wholesale distribution business with a 50-state title model and a tribal 8(a) teaming agreement for federal set-aside contracts. VICP also signed a definitive agreement to acquire the FDA-approved NitroMist lingual aerosol for a $2.0 million convertible note, with closing pending FDA acknowledgment of NDA transfer. The company is in discussions to acquire a 120,000 sq ft manufacturing facility in Puerto Rico, which would enable in-house production. This transforms VICP from a legacy biotech into a vertically integrated pharmaceutical platform targeting underserved federal, tribal, and rural markets. Key risks include the pending FDA transfer, facility acquisition, and NitroMist relaunch requirements.
At the time of this announcement, VICP was trading at $0.85 on OTC in the Life Sciences sector, with a market capitalization of approximately $27.5M. The 52-week trading range was $0.00 to $200.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.